Trial Profile
VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Bacteraemia; Bacterial infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
- Focus Adverse reactions
- Sponsors Astellas Pharma; Cumberland Pharmaceuticals; Innoviva
- 14 Oct 2020 Planned End Date changed from 1 Dec 2025 to 1 Oct 2020.
- 14 Oct 2020 Planned primary completion date changed from 1 Dec 2025 to 1 Oct 2020.
- 14 Oct 2020 Status changed from recruiting to withdrawn prior to enrolment.